In terms of treatability, TSC1-, TSC2-, SLC35A2-, ATP7A-, ALDH7A1-, and MMACHC-related disorders had specific therapeutic regimens and accounted for 18.5% (19/103) of the cases with genetic disorders. This evidence concerns the gene ATP7A and hereditary disease.